We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants (GENBPD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Centre Hospitalier Intercommunal Creteil.
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT00904774
First Posted: May 20, 2009
Last Update Posted: May 20, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Centre Hospitalier Intercommunal Creteil
May 19, 2009
May 20, 2009
May 20, 2009
May 2009
Not Provided
bronchopulmonary dysplasia [ Time Frame: 36 weeks of postconceptional age ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants
Polymorphisms of Genes Controlling Alveolar Development and Risk of Bronchopulmonary Dysplasia

Despite considerable obstetric and neonatal advances in the care of very low birth weight (VLBW) neonates, bronchopulmonary dysplasia (BPD) continues to occur among 20 to 40% of surviving infants, and new ways for combatting this disease must be found. BPD appears to result from arrested lung development, but its etiology has not yet been fully established. Besides the role of the exposure of the immature lung to injurious factors in the development of BPD, a genetic susceptibility for BPD in preterm infants was recently evidenced. Taking advantage of new genomic technologies, the objective of the investigators' project is to identify predisposing human genetic variants through:

  1. a genome-wide association (GWA) study in VLBW neonates,
  2. a candidate-gene association study, including selection of single nucleotide polymorphisms (SNPs) found in (a) and
  3. functional studies of any SNP found to be convincingly associated with BPD in (a) and (b).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Premature neonates
Bronchopulmonary Dysplasia
Not Provided
premature neonates
gestational age less than 28 weeks
Hadchouel A, Decobert F, Franco-Montoya ML, Halphen I, Jarreau PH, Boucherat O, Martin E, Benachi A, Amselem S, Bourbon J, Danan C, Delacourt C. Matrix metalloproteinase gene polymorphisms and bronchopulmonary dysplasia: identification of MMP16 as a new player in lung development. PLoS One. 2008 Sep 11;3(9):e3188. doi: 10.1371/journal.pone.0003188.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
800
Not Provided
Not Provided

Inclusion Criteria:

  • Gestational age < 28 weeks
  • Inborn birth
  • Prophylactic administration of surfactant in the delivery room
  • Written informed consent obtained from parents

Exclusion Criteria:

  • Gestational age of 28 weeks or more
  • Outborn birth
  • No prophylactic administration of surfactant in the delivery room
  • Congenital malformation
  • Absence of written informed consent obtained from parents
Sexes Eligible for Study: All
up to 8 Weeks   (Child)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00904774
AOR 07 018
Not Provided
Not Provided
Not Provided
Delacourt, Christophe, MD, PhD, INSERM U955
Centre Hospitalier Intercommunal Creteil
Not Provided
Not Provided
Centre Hospitalier Intercommunal Creteil
May 2009